AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment aimed at alleviating menopausal hot flashes.
AbCellera Biologics Stock Rises After Positive Data, Capital Raise
This news comes as the broader healthcare sector is experiencing a modest gain of 0.17%, contributing to the stock’s upward movement in a generally stable market environment.
On Wednesday, AbCellera Biologics commenced an underwritten public offering of $200 million of its common shares and pre-funded warrants.
AbCellera will use the net proceeds from the offering to fund the continued research, development and clinical advancement of its internal pipeline, including its lead clinical program, ABCL635, as well as for working capital and other general corporate purposes.
The trial results released on Tuesday indicate that ABCL635 has established a new efficacy benchmark for treating menopausal symptoms, which could position AbCellera favorably in the competitive healthcare landscape.
ABCL Technical Outlook: Bullish Trend And Overbought Signals
From a technical perspective, AbCellera Biologics is currently trading at $9.93, significantly above its key moving averages.
The stock is 56.3% above its 20-day simple moving average (SMA) of $6.45 and 121.2% above its 200-day SMA of $4.56, indicating a strong bullish trend.
The Relative Strength Index (RSI) is at 79.22, suggesting that the stock is overbought, which could lead to a potential pullback if momentum shifts.
Additionally, the 50-day SMA has crossed above the 200-day SMA, confirming a golden cross in June, a bullish signal that typically indicates a strong upward trend.
The stock’s recent performance has also seen a 12-month increase of 136.07%, showcasing its robust growth trajectory over the past year.
Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $14.60. Recent analyst moves include:
- Truist Securities: Buy (Raises Target to $30.00) (Aug. 11)
- Stifel: Buy (Raises Target to $9.00) (Aug. 6)
- Cantor Fitzgerald: Overweight (Raises Target to $12.00) (Aug. 6)
How ABCL Ranks On Momentum Versus The Market
Below is the Benzinga Edge scorecard for AbCellera Biologics, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Bullish (Score: 98.69) — Stock is outperforming the broader market.
The Verdict: AbCellera Biologics’ Benzinga Edge signal reveals a strong momentum-driven story, indicating robust performance relative to the market. This suggests that the stock is currently in a favorable position for traders looking for growth opportunities.
ABCL Price Action: AbCellera Biologics shares were up 1.69% to $9.92 at the time of publication on Wednesday. The stock is trading near its 52-week high of $10.29, according to Benzinga Pro data.
Photo: PeopleImages.com – Yuri A via Shutterstock
